“BeyondSpring reported 4Q17 with a net loss of $16.5M and ended the period with $30.6M in cash. Operating expenses for the year were $98M but included $42.3M for the remaining interest in Plinabulin and $18M in stock-based compensation. We estimate the company has runway into late 2018 and through the next catalysts.”,” Maxim Group’s analyst wrote.
A number of other brokerages have also issued reports on BYSI. Seaport Global Securities began coverage on BeyondSpring in a research note on Tuesday, December 5th. They issued a buy rating and a $56.00 price target on the stock. HC Wainwright set a $60.00 price target on BeyondSpring and gave the stock a buy rating in a research note on Monday, December 4th. Finally, Zacks Investment Research raised BeyondSpring from a sell rating to a hold rating in a research note on Tuesday, January 9th. Five analysts have rated the stock with a buy rating, The stock has a consensus rating of Buy and a consensus price target of $49.60.
BeyondSpring (NASDAQ:BYSI) last issued its quarterly earnings results on Tuesday, April 3rd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.06). equities analysts predict that BeyondSpring will post -2.91 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “BeyondSpring (BYSI) Given a $52.00 Price Target at Maxim Group” was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/3338418/beyondspring-bysi-given-a-52-00-price-target-at-maxim-group.html.
BeyondSpring Company Profile
BeyondSpring Inc, a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced NSCLC; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab.
Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.